OncoMatch/Clinical Trials/NCT05384821
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
Is NCT05384821 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for wilms tumor.
Treatment: Vincristine · Irinotecan · Temozolomide · Etoposide · Cis-Retinoic acid — This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Demographics
Prior therapy
Must have received: chemotherapy
After at least 2 lines of chemotherapy (conventional or high dose, which may include the trial molecules) or after 1 line for high risk relapse for which there would not be any curative therapy. If 1 line for high risk relapse, the enrolment should be confirmed by coordinators.
Cannot have received: chemotherapy or radiotherapy of target lesion
Chemotherapy or radiotherapy of target lesion within 3 weeks prior to inclusion
Cannot have received: target therapy
Target therapy within less than 5 * half-life of the substance prior to inclusion
Lab requirements
Blood counts
Neutrophils > 1000/mm3; Platelets > 75,000/mm3
Kidney function
Creatinine ≤ 1.5 ULN or clearance ≥ 60 mL/min/1.73m2 (In case of doubt, to be confirm by assessment of cystatin)
Liver function
Transaminases (ALT/AST) ≤ 3 times ULN (or ≤ 6 times ULN if liver metastasis); total bilirubin ≤ 2 ULN (except in case of Gilbert's disease)
Adequate biological criteria: Neutrophils > 1000/mm3; Platelets > 75,000/mm3; Transaminases (ALT/AST) ≤ 3 times ULN (or ≤ 6 times ULN if liver metastasis); total bilirubin ≤ 2 ULN (except in case of Gilbert's disease); Creatinine ≤ 1.5 ULN or clearance ≥ 60 mL/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05384821 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy or radiotherapy of target lesion, target therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify